Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

348255

registered interest
date	03/06/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Mental Health Services: West Midlands
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what plans his Department has to review mental health provision in the West Midlands; and if he will make a statement.
tabling member constituency	Coventry South
tabling member printed	Mr Jim Cunningham
uin	1026
answer	answer is ministerial correction date of answer 08/06/2015 answer text <p>This is a matter for the National Health Service locally. NHS England advises that Coventry and Rugby Clinical Commissioning Group (CCG), is working along with South Warwickshire CCG, Warwickshire North CCG, Coventry City Council and Warwickshire County Council, on a joint review of the specifications for children and adolescent mental health services.</p><p> </p><p> </p><p> </p><p>In the current financial year Coventry and Rugby CCG will put an additional £1.2 million towards the mental health services it commissions.</p><p> </p> answering member constituency North East Bedfordshire answering member printed Alistair Burt grouped question UIN 1027 question first answered 08/06/2015 14:24:51 answering member 1201 label Biography information for Alistair Burt
tabling member	308 label Biography information for Mr Jim Cunningham

348256

registered interest
date	03/06/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Mental Health Services: West Midlands
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what plans his Department has to make additional resources available for mental health services in the West Midlands over the next five years; and if he will make a statement.
tabling member constituency	Coventry South
tabling member printed	Mr Jim Cunningham
uin	1027
answer	answer is ministerial correction date of answer 08/06/2015 answer text <p>This is a matter for the National Health Service locally. NHS England advises that Coventry and Rugby Clinical Commissioning Group (CCG), is working along with South Warwickshire CCG, Warwickshire North CCG, Coventry City Council and Warwickshire County Council, on a joint review of the specifications for children and adolescent mental health services.</p><p> </p><p> </p><p> </p><p>In the current financial year Coventry and Rugby CCG will put an additional £1.2 million towards the mental health services it commissions.</p><p> </p> answering member constituency North East Bedfordshire answering member printed Alistair Burt grouped question UIN 1026 question first answered 08/06/2015 14:24:51 answering member 1201 label Biography information for Alistair Burt
tabling member	308 label Biography information for Mr Jim Cunningham

348257

registered interest
date	03/06/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Antimicrobials: Drug Resistance
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what plans his Department has to make additional funding available to tackle drug-resistant infections over the next five years.
tabling member constituency	Coventry South
tabling member printed	Mr Jim Cunningham
uin	1028
answer	answer is ministerial correction date of answer 08/06/2015 answer text <p>The health and care system across the United Kingdom is taking action against the growing threat of infections that are resistant to the antimicrobial drugs used to treat them.</p><p> </p><p> </p><p> </p><p>In December 2014, we published the UK Five Year AMR Strategy detailed implementation plan. The plan set out those activities that needed to be undertaken to deliver the strategy in each of seven key areas for action. Activity in the plan is led by the Department of Health, Public Health England, Department for Environment, Food and Rural Affairs and NHS England and is incorporated within existing business plans for those organisations.</p><p> </p><p> </p><p> </p><p>The Government has no current plans to make additional funding available to tackle drug-resistant infections. Any proposals for funding would be subject to the outcome of the Spending Review later this year.</p><p> </p><p> </p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 08/06/2015 10:54:59 answering member 3918 label Biography information for Jane Ellison
tabling member	308 label Biography information for Mr Jim Cunningham

348258

registered interest
date	03/06/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Infectious Diseases
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what estimate he has made of the number of drug-resistant infections (a) in the West Midlands and (b) nationally in the next five years.
tabling member constituency	Coventry South
tabling member printed	Mr Jim Cunningham
uin	1029
answer	answer is ministerial correction date of answer 08/06/2015 answer text <p>Public Health England (PHE) has published no estimates for the number of drug-resistant infections in the West Midlands or nationally over the next five years. The science of drug resistant infections is incompletely understood and is rapidly changing and evolving. Multi-drug resistant infections are unpredictable in their occurrence and can rapidly change. For these reasons producing estimates of the likely burden in future years is unlikely to be meaningful or robust.</p><p> </p><p> </p><p> </p><p>Antimicrobial resistance is a priority for PHE who are working to improve surveillance and knowledge in this area. Specific antimicrobial resistant infections have been measured by PHE and openly published in weekly Health Protection Reports.</p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 08/06/2015 10:58:32 answering member 3918 label Biography information for Jane Ellison
tabling member	308 label Biography information for Mr Jim Cunningham

348397

registered interest
date	03/06/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Hidradenitis Suppurativa: Health Education
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what steps his Department is taking to raise awareness of hidradenitis suppurativa.
tabling member constituency	West Lancashire
tabling member printed	Rosie Cooper
uin	962
answer	answer is ministerial correction date of answer 08/06/2015 answer text <p>Hidradenitis suppurativa (HS) affects around 90,000 people in England. The Department’s National Institute for Health Research Clinical Research Network (CRN) is providing research infrastructure to enable molecular genetic analysis of HS, although expenditure on this cannot be disaggregated from total CRN spend.</p><p> </p><p><br> Information on the diagnosis, treatment care and support of patients with HS can be found on the NHS Choices website. This also provides links to the British Association of Dermatologists, which has produced a patient information leaflet on HS, and the HS Trust, which is the United Kingdom‘s leading charity for the condition. More information can be found at the following link:</p><p> </p><p><br> <a href="http://www.nhs.uk/conditions/hidradenitis-suppurativa/Pages/Introduction.aspx" target="_blank">www.nhs.uk/conditions/hidradenitis-suppurativa/Pages/Introduction.aspx</a></p><p> </p><p><br> In terms of the care pathway for the condition, HS can usually be managed with treatments including antibiotics, antiseptic washes and immunosuppressive treatments such as steroids or ciclosporin, which a general practitioner may prescribe. For those patients with the most serious forms of HS who cannot be managed through routine access to treatments provided through primary or secondary care, a referral to a specialised dermatology service may be appropriate. NHS England commissions services for people with rare and complex skin conditions and has set out what providers must have in place in order to offer specialist dermatology care. These services may provide more intensive therapies with the involvement of a range of health and care professionals, subject to a patient’s needs. More information can be found at the following link:</p><p> </p><p> </p><p> </p><p><a href="http://www.england.nhs.uk/wp-content/uploads/2013/06/a12-spec-dermatology.pdf" target="_blank">www.england.nhs.uk/wp-content/uploads/2013/06/a12-spec-dermatology.pdf</a></p><p> </p> answering member constituency Battersea answering member printed Jane Ellison grouped question UIN 963 964 965 question first answered 08/06/2015 10:53:58 answering member 3918 label Biography information for Jane Ellison
tabling member	1538 label Biography information for Rosie Cooper

348398

registered interest
date	03/06/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Hidradenitis Suppurativa
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what estimate his Department has made of the number of people with hidradenitis suppurativa in the UK; how much his Department has spent on research into hidradenitis suppurativa in the last four years; and what guidance his Department gives on support to be given through the NHS for people with hidradenitis suppurativa.
tabling member constituency	West Lancashire
tabling member printed	Rosie Cooper
uin	963
answer	answer is ministerial correction date of answer 08/06/2015 answer text <p>Hidradenitis suppurativa (HS) affects around 90,000 people in England. The Department’s National Institute for Health Research Clinical Research Network (CRN) is providing research infrastructure to enable molecular genetic analysis of HS, although expenditure on this cannot be disaggregated from total CRN spend.</p><p> </p><p><br> Information on the diagnosis, treatment care and support of patients with HS can be found on the NHS Choices website. This also provides links to the British Association of Dermatologists, which has produced a patient information leaflet on HS, and the HS Trust, which is the United Kingdom‘s leading charity for the condition. More information can be found at the following link:</p><p> </p><p><br> <a href="http://www.nhs.uk/conditions/hidradenitis-suppurativa/Pages/Introduction.aspx" target="_blank">www.nhs.uk/conditions/hidradenitis-suppurativa/Pages/Introduction.aspx</a></p><p> </p><p><br> In terms of the care pathway for the condition, HS can usually be managed with treatments including antibiotics, antiseptic washes and immunosuppressive treatments such as steroids or ciclosporin, which a general practitioner may prescribe. For those patients with the most serious forms of HS who cannot be managed through routine access to treatments provided through primary or secondary care, a referral to a specialised dermatology service may be appropriate. NHS England commissions services for people with rare and complex skin conditions and has set out what providers must have in place in order to offer specialist dermatology care. These services may provide more intensive therapies with the involvement of a range of health and care professionals, subject to a patient’s needs. More information can be found at the following link:</p><p> </p><p> </p><p> </p><p><a href="http://www.england.nhs.uk/wp-content/uploads/2013/06/a12-spec-dermatology.pdf" target="_blank">www.england.nhs.uk/wp-content/uploads/2013/06/a12-spec-dermatology.pdf</a></p><p> </p> answering member constituency Battersea answering member printed Jane Ellison grouped question UIN 962 964 965 question first answered 08/06/2015 10:54:00 answering member 3918 label Biography information for Jane Ellison
tabling member	1538 label Biography information for Rosie Cooper

348399

registered interest
date	03/06/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Hidradenitis Suppurativa: Health Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what assessment his Department has made of the effectiveness of the care pathways for patients with hidradenitis suppurativa.
tabling member constituency	West Lancashire
tabling member printed	Rosie Cooper
uin	964
answer	answer is ministerial correction date of answer 08/06/2015 answer text <p>Hidradenitis suppurativa (HS) affects around 90,000 people in England. The Department’s National Institute for Health Research Clinical Research Network (CRN) is providing research infrastructure to enable molecular genetic analysis of HS, although expenditure on this cannot be disaggregated from total CRN spend.</p><p> </p><p><br> Information on the diagnosis, treatment care and support of patients with HS can be found on the NHS Choices website. This also provides links to the British Association of Dermatologists, which has produced a patient information leaflet on HS, and the HS Trust, which is the United Kingdom‘s leading charity for the condition. More information can be found at the following link:</p><p> </p><p><br> <a href="http://www.nhs.uk/conditions/hidradenitis-suppurativa/Pages/Introduction.aspx" target="_blank">www.nhs.uk/conditions/hidradenitis-suppurativa/Pages/Introduction.aspx</a></p><p> </p><p><br> In terms of the care pathway for the condition, HS can usually be managed with treatments including antibiotics, antiseptic washes and immunosuppressive treatments such as steroids or ciclosporin, which a general practitioner may prescribe. For those patients with the most serious forms of HS who cannot be managed through routine access to treatments provided through primary or secondary care, a referral to a specialised dermatology service may be appropriate. NHS England commissions services for people with rare and complex skin conditions and has set out what providers must have in place in order to offer specialist dermatology care. These services may provide more intensive therapies with the involvement of a range of health and care professionals, subject to a patient’s needs. More information can be found at the following link:</p><p> </p><p> </p><p> </p><p><a href="http://www.england.nhs.uk/wp-content/uploads/2013/06/a12-spec-dermatology.pdf" target="_blank">www.england.nhs.uk/wp-content/uploads/2013/06/a12-spec-dermatology.pdf</a></p><p> </p> answering member constituency Battersea answering member printed Jane Ellison grouped question UIN 962 963 965 question first answered 08/06/2015 10:54:00 answering member 3918 label Biography information for Jane Ellison
tabling member	1538 label Biography information for Rosie Cooper

348400

registered interest
date	03/06/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Hidradenitis Suppurativa: Health Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what steps his Department has taken to provide information to surgeons, dermatologists and general practitioners about hidradenitis suppurativa.
tabling member constituency	West Lancashire
tabling member printed	Rosie Cooper
uin	965
answer	answer is ministerial correction date of answer 08/06/2015 answer text <p>Hidradenitis suppurativa (HS) affects around 90,000 people in England. The Department’s National Institute for Health Research Clinical Research Network (CRN) is providing research infrastructure to enable molecular genetic analysis of HS, although expenditure on this cannot be disaggregated from total CRN spend.</p><p> </p><p><br> Information on the diagnosis, treatment care and support of patients with HS can be found on the NHS Choices website. This also provides links to the British Association of Dermatologists, which has produced a patient information leaflet on HS, and the HS Trust, which is the United Kingdom‘s leading charity for the condition. More information can be found at the following link:</p><p> </p><p><br> <a href="http://www.nhs.uk/conditions/hidradenitis-suppurativa/Pages/Introduction.aspx" target="_blank">www.nhs.uk/conditions/hidradenitis-suppurativa/Pages/Introduction.aspx</a></p><p> </p><p><br> In terms of the care pathway for the condition, HS can usually be managed with treatments including antibiotics, antiseptic washes and immunosuppressive treatments such as steroids or ciclosporin, which a general practitioner may prescribe. For those patients with the most serious forms of HS who cannot be managed through routine access to treatments provided through primary or secondary care, a referral to a specialised dermatology service may be appropriate. NHS England commissions services for people with rare and complex skin conditions and has set out what providers must have in place in order to offer specialist dermatology care. These services may provide more intensive therapies with the involvement of a range of health and care professionals, subject to a patient’s needs. More information can be found at the following link:</p><p> </p><p> </p><p> </p><p><a href="http://www.england.nhs.uk/wp-content/uploads/2013/06/a12-spec-dermatology.pdf" target="_blank">www.england.nhs.uk/wp-content/uploads/2013/06/a12-spec-dermatology.pdf</a></p><p> </p> answering member constituency Battersea answering member printed Jane Ellison grouped question UIN 962 963 964 question first answered 08/06/2015 10:54:01 answering member 3918 label Biography information for Jane Ellison
tabling member	1538 label Biography information for Rosie Cooper

347975

registered interest
date	02/06/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Health Professions
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what assessment he has made of the number of physician associates employed in the NHS in (a) Hertfordshire and (b) England.
tabling member constituency	Stevenage
tabling member printed	Stephen McPartland
uin	808
answer	answer is ministerial correction date of answer 08/06/2015 answer text <p>This information is not held centrally by the Department.</p><p> </p><p> </p><p> </p><p>As at 3 June 2015, there are 152 qualified physician associates (PAs) registered on the Physician Associate Voluntary Register. This voluntary register does not provide information on whether any of these PAs are currently employed in the National Health Service.</p><p> </p><p> </p><p> </p><p>For 2015-16, Health Education England will commission 205 PA training posts, representing an increase of 754% upon last year. With a two year training programme, successful trainees will become available for employment in 2017-18.</p><p> </p> answering member constituency Ipswich answering member printed Ben Gummer question first answered 08/06/2015 11:00:42 answering member 3988 label Biography information for Ben Gummer
tabling member	4093 label Biography information for Stephen McPartland

347979

registered interest
date	02/06/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Paediatrics
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what steps he is taking to improve the diagnosis process and reduce the time taken of children going through paediatric care pathways.
tabling member constituency	Birkenhead
tabling member printed	Frank Field
uin	749
answer	answer is ministerial correction date of answer 08/06/2015 answer text <p>This Government is committed to improving health outcomes for children and young people, and there is a wide range of ongoing activity to improve the responsiveness of the National Health Service in the diagnosis and treatment of children on care pathways. This includes support for the development by the Royal College of Paediatrics and Child Health of Paediatric Care Online, a resource for the clinical workforce across the full range of children’s health issues. This will be launched later in 2015 and is expected to make a real improvement to the consistency and effectiveness of paediatric care.</p><p> </p><p> </p><p> </p><p>In addition the Government is committed to improving access to psychological therapies (IAPT) for children and young people. The new waiting standards for Early Intervention in Psychosis (so that 50% of people who experience first time psychosis receive a National Institute for Health and Care Excellence approved care package within two weeks) came into effect on 1 April 2015 and NHS England is aiming to expand the children and young people’s IAPT programme to cover the whole country by 2018.</p><p> </p><p> </p><p> </p><p>NHS England is looking at the impact on cancer outcomes of early diagnosis projects, and is working on the early diagnosis of sepsis, and detection of the deteriorating child. In addition NHS England has a very active and appropriately scrutinised process for the governance surrounding Paediatric Specialist Services.</p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 08/06/2015 13:54:01 answering member 3918 label Biography information for Jane Ellison
tabling member	478 label Biography information for Lord Field of Birkenhead